Galvin Roy 4/A

4/A · HAEMONETICS CORP · Filed Jun 13, 2025

Form 4/AAmended

Period: 2025-05-16

EVP, Chief Commercial Officer

Transactions

Award
Non-qualified Stock Option (Right to Buy)
2025-05-16+12,317→ 12,317 total
Exercise: $70.31Exp: 2032-05-16→ Common Stock (12,317 underlying)
Award
Common Stock
2025-05-16+5,689→ 12,932 total

Footnotes (6)

[F1]The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
[F2]On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 6,755 instead of 5,689. This net decrease of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person.
[F3]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
[F4]This number includes unvested RSUs previously reported.
[F5]On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 14,626 instead of 12,317. This net decrease of 2,309 options will be reflected in future filings by the reporting person.
[F6]Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

Documents

1 file